AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Neuronal acetylcholine receptor subunit alpha-9

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UGM1

UPID:

ACHA9_HUMAN

Alternative names:

Nicotinic acetylcholine receptor subunit alpha-9

Alternative UPACC:

Q9UGM1; Q14CY7; Q4W5A2; Q9NYV2

Background:

The Neuronal acetylcholine receptor subunit alpha-9, identified by the accession number Q9UGM1, plays a pivotal role in auditory processing. This ionotropic receptor modulates auditory stimuli through a conformation change upon agonist binding, leading to the opening of an ion-conducting channel. It is permeable to divalent cations, including calcium, which may activate a potassium current, hyperpolarizing the cell membrane. This process is crucial in reducing basilar membrane motion, potentially protecting against acoustic trauma.

Therapeutic significance:

Understanding the role of Neuronal acetylcholine receptor subunit alpha-9 could open doors to potential therapeutic strategies, particularly in the realm of auditory health and protection against acoustic trauma.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.